fluoxetine has been researched along with lorazepam in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ansseau, M; Bartholomé, F; Bataille, M; Charles, G; Darimont, P; De Wilde, J; Devoitille, JM; Papart, P; Schittecatte, M; Troisfontaines, B | 1 |
| Kingsbury, SJ; Puckett, KM | 1 |
| Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L | 1 |
| Bader, PI; Cangany, N; Dougherty, S; Jackson, CE; Raymond, G | 1 |
| Beijnen, JH; Kerbusch, T; Mathôt, RA; Meesters, EW; Otten, HM; Schellens, JH; van Kan, HJ | 1 |
| Mar, A; Rochford, J; Spreekmeester, E | 1 |
| Eich, P; Eichhorn, M | 1 |
| Preskorn, SH | 1 |
| Bodeau, N; Bonnot, O; Cohen, D; Consoli, A; Gheorghiev, C; Jutard, C; Kloeckner, A; Pitron, V | 1 |
| Chou, KR; Chun Tsai, H; Hua Chang, H; Huang, SY; Hung Chi, M; Kuang Yang, Y; Lu, RB; See Chen, P; Tzeng, NS | 1 |
| Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, CL; Wang, LJ; Wang, TY; Yang, YK | 1 |
| Ford, N; Galletly, C; Ludbrook, G | 1 |
| Martin, KM | 1 |
1 review(s) available for fluoxetine and lorazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for fluoxetine and lorazepam
| Article | Year |
|---|---|
Controlled comparison of milnacipran and fluoxetine in major depression.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Lorazepam; Male; Middle Aged; Milnacipran; Patient Dropouts; Psychiatric Status Rating Scales | 1994 |
Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naïve patients with bipolar II disorder after a twelve-week pharmacological intervention.
Topics: Adult; Affect; Bipolar Disorder; Body Mass Index; Brain-Derived Neurotrophic Factor; Cholesterol; Female; Fluoxetine; Humans; Linear Models; Lipoproteins, LDL; Longitudinal Studies; Lorazepam; Male; Metabolic Syndrome; Psychiatric Status Rating Scales; Treatment Outcome; Valproic Acid | 2015 |
16 other study(ies) available for fluoxetine and lorazepam
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Effects of fluoxetine on serum clozapine levels.
Topics: Adult; Clonazepam; Clozapine; Drug Interactions; Drug Therapy, Combination; Epilepsies, Myoclonic; Fluoxetine; Humans; Lorazepam; Male; Schizophrenia, Paranoid | 1995 |
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Desipramine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Imipramine; Lorazepam; Male; Panic Disorder; Retrospective Studies; Treatment Outcome | 1994 |
Infantile refsum disease in four Amish sibs.
Topics: Adolescent; Antidepressive Agents; Child; Consanguinity; Female; Fluoxetine; Humans; Lorazepam; Male; Refsum Disease; Risperidone | 2000 |
Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.
Topics: Acute Disease; Acute Kidney Injury; Adult; Antimanic Agents; Antipsychotic Agents; Bayes Theorem; Bipolar Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Lithium; Lorazepam; Male; Models, Biological; Renal Dialysis; Risperidone; Suicide, Attempted | 2002 |
Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Environment; Fluoxetine; Habituation, Psychophysiologic; Lighting; Lorazepam; Male; Olfaction Disorders; Olfactory Bulb; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2002 |
[Dextromethorphane intoxication under co-medication with cytochrome P450-inhibitor fluoxetin: prolonged and accentuated signs of intoxication].
Topics: Adult; Antitussive Agents; Cytochrome P-450 Enzyme Inhibitors; Depressive Disorder, Major; Dextromethorphan; Drug Overdose; Female; Fluoxetine; Humans; Lorazepam; Metabolic Clearance Rate; Suicide, Attempted | 2002 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; Dementia; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Haloperidol; Hospitalization; Humans; Hypnotics and Sedatives; Lorazepam; Parkinson Disease; Psychomotor Agitation; Selegiline; Trihexyphenidyl | 2008 |
Lorazepam, fluoxetine and packing therapy in an adolescent with pervasive developmental disorder and catatonia.
Topics: Adolescent; Catatonia; Child; Child Development Disorders, Pervasive; Fluoxetine; GABA Modulators; Humans; Lorazepam; Male; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Follow-Up Studies; Humans; Lorazepam; Male; Metabolic Syndrome; Prevalence; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Ketamine; Lithium Compounds; Lorazepam; Middle Aged; Quetiapine Fumarate | 2015 |
Animal Behavior Case of the Month. Reactional urine marking.
Topics: Aggression; Animals; Anti-Anxiety Agents; Cats; Eliminative Behavior, Animal; Female; Fluoxetine; Lorazepam; Male; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Territoriality | 2015 |